Alkermes (FRA:8AK) YoY EBITDA Growth : -44.44% (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Alkermes YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Alkermes's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -44.44%.

Alkermes's EBITDA per Share for the three months ended in Mar. 2025 was €0.18.

Alkermes YoY EBITDA Growth Historical Data

The historical data trend for Alkermes's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes YoY EBITDA Growth Chart

Alkermes Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

Get a 7-Day Free Trial

94.75

3,177.42

-63.84

713.62

-0.50

Alkermes Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
YoY EBITDA Growth	Get a 7-Day Free Trial															350.00	-57.37	3.91	128.51	-44.44

Alkermes YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Alkermes's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(2.793	-	2.807)	/	\| 2.807 \|
=	-0.50 %

Alkermes's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2025 )
=	(EBITDA per Share (Q: Mar. 2025 )	-	EBITDA per Share (Q: Mar. 2024 ))	/	\| EBITDA per Share (Q: Mar. 2024 )) \|
=	(0.18	-	0.324)	/	\| 0.324 \|
=	-44.44 %

Alkermes YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Alkermes's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Alkermes Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (FRA:8AK) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

ALKS:USA 8AK:Germany

Address

1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6

Website

https://www.alkermes.com

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Alkermes Headlines

No Headlines